JPRN-UMIN000005308已完成未知
Randomized phase II study of Erlotinib vs. S-1 for non-small lung cancer after failure of two or three prior - Randomized phase II study of Erlotinib vs. S-1 for non-small lung cancer after failure of two or three prior
Hokkaido Lung Cancer Clinical Study Group0 个研究点目标入组 60 人开始时间: 2011年3月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Previous histories of drug allergy, which may increase the risk of this study. 2)Serious concomitant infection. 3)Usages of oral steroids or immunosuppressive drugs. 4)Serious complications including severe cardiovascular disease, cerebrovascular disease, severe hypertension, active peptic ulcer, uncontrolled diabetes. 5)Interstitial pneumonia or pulmonary fibrosis on chest CT scans. 6)Patients with EGFR mutation or having past history of administration of EGFR tyrosine kinase inhibitors. 7)Severe pleural, abdominal or cardiac effusion. 8) Patients with symptomatic brain metastasis 9)Patients with active concomitant malignancy 10)Pregnant, lactating women. 11)Inappropriate patients judged by physicians
研究者
相似试验
已完成
2 期
A randomized phase II study of Erlotinib with or without Bevacizumab in NSCLC patients previouly treated with platinum-based chemotherapy containing bevacizumab. North Japan Lung Cancer Study Group Trial 1201JPRN-UMIN000007475orth Japan Lung Cancer Study Group64
进行中（未招募）
不适用
A randomized phase II study of erlotinib compared to single agent chemotherapy-erlotinib combination in pretreated patients with advanced NSCLC (NVALT10 study) - NVALT10patients who failed previous cytotoxic treatment for non-small-cell lung cancer locally advanced and metastatic disease stage IIIB and IVMedDRA version: 9.1Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBMedDRA version: 9.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVEUCTR2009-009315-22-NLVALT230
进行中（未招募）
1 期
A Randomized Phase 2 Study Comparing Erlotinib-Pemetrexed, Pemetrexed alone, and Erlotinib alone, as Second-Line Treatment for Non-Smoker Patients with Locally Advanced or Metastatic Non-Small Cell Lung CancerEUCTR2007-003912-72-GBEli Lilly and Company Limited237
进行中（未招募）
不适用
A Randomized Phase 2 Study of Erlotinib plus ARQ 197 versus Erlotinib plus Placebo in Previously Treated Patients with Locally Advanced or Metastatic Non-Small Cell Lung CancerEUCTR2007-004634-17-LVArQule Inc.154
进行中（未招募）
不适用
A Randomized Phase 2 Study of Erlotinib plus ARQ 197 versus Erlotinib plus Placebo in Previously Treated Patients with Locally Advanced or Metastatic Non-Small Cell Lung Canceron-Small Cell Lung Cancer (phase 3b/4)MedDRA version: 9.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBMedDRA version: 9.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2007-004634-17-DEArQule Inc.193